ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Amgen Says Recent Sensipar Study Failed to Meet Primary Endpoint

By Mia Lamar Amgen Inc. (AMGN) said Friday that a study evaluating its Sensipar drug for effectiveness in reducing the risk of mortality and cardiovascular events in patients suffering from chronic kidney disease failed to meet its primary endpoint. Sensipar--which is marketed as Mimpara in Europe--was first approved in 2004 to treat thyroid problems in patients with kidney disease and cancer. The company recorded $808 million in global sales of the drug last year. Amgen said Friday it undertook the Phase 3 trial of Sensipar to discover whether the drug could positively impact the high rates of mortality and incidences like heart failure experienced by patients with chronic kidney disease that are receiving dialysis. Results, however, were not statistically significant, Amgen said. The company noted analyses from the study are ongoing and will be submitted for presentation at a major medical meeting later this year. Amgen, the biggest stand-alone biotechnology company, has been pursuing deals to bolster its research-and-development pipeline as sales growth slows for older drugs. Shares were recently off 26 cents to $68.84. Write to Mia Lamar at mia.lamar@dowjones.com

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
03/30/201510:18:24FDA accepts Amgen's Kyprolis sNDA under Priority Review
03/30/201509:00:00FDA Grants Amgen Priority Review for Kyprolis® (Carfilzomib...
03/30/201508:00:43European regulator validates Biogen's marketing application for...
03/30/201507:40:16Nonfarm Payrolls Will Be Closely Watched - Cramer's Mad Money...
03/28/201515:03:023 Top Stocks for Obamacare Lovers
03/28/201512:03:025 Freakishly Expensive Cancer Drugs
03/28/201508:02:02Could These Experimental Drugs Eclipse Harvoni's Historic Launch?
03/26/201521:09:30Portfolio Changes For The First Quarter Of 2015
03/26/201516:01:00Cancer Survivor Joan Lunden Named 2015 Honorary Breakaway From...
03/23/201520:21:07Amgen Is The Stock Of The Week
03/23/201517:44:29This Market Could Grow 6250% in 10 Years
03/23/201515:25:55Why ImmunoGen Inc. is Soaring Higher Today
03/23/201512:25:04Why ImmunoGen Inc. is Soaring Higher Today
03/23/201512:14:41Why ImmunoGen, Inc. is Soaring Higher Today
03/23/201510:14:03This Market Could Grow 6250% in 10 Years
03/23/201509:00:00Amgen To Webcast Investor Call At the 73rd Annual Meeting of...
03/23/201507:30:40Biogen Idec shortens name; CEO says drug candidates in neurodegenerative...
03/21/201512:04:06Dividend Stocks: 2 to Avoid, 1 to Buy
03/21/201511:02:02Drug Spending Is Soaring: 3 Takeaways You Can't Miss
03/20/201509:00:00Amgen Submits Application For Investigational LDL Cholesterol-Lowering...

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad